GlassScriptPhysician profile
Steven T Rosen
NPI 1811968126
$95,358.72
in general payments reported to CMS, 2019-2025
28 companies · $857 in 2025
The $857 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,786 · 2020: $1,523 · 2021: $7,210 · 2022: $3,351 · 2023: $74K · 2024: $463 · 2025: $857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $70K · Food and Beverage: $3,526 · Consulting Fee: $1,875 · Education: $87.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $70,000.00 |
| Food and Beverage | $3,526.23 |
| Consulting Fee | $1,875.00 |
| Education | $87.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $71,381.27 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $6,938.47 | 2019-2025 | Calquence |
| Verastem, INC. | $5,157.47 | 2019 | |
| Abbvie INC. | $2,326.15 | 2022-2025 | |
| Tg Therapeutics, INC. | $2,229.98 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $1,627.44 | 2019 | |
| Adaptive Biotechnologies Corporation | $1,500.00 | 2020 | |
| Genentech USA, INC. | $682.20 | 2019-2025 | Columvi, Polivy, Lunsumio |
| Kyowa Kirin, INC. | $550.15 | 2019-2023 | Poteligeo |
| Seagen INC. | $455.92 | 2019-2022 | |
| Beigene USA, INC. | $356.50 | 2022-2023 | Brukinsa |
| Janssen Scientific Affairs, LLC | $317.20 | 2022-2023 | Imbruvica |
| Kite Pharma, INC. | $307.67 | 2019 | |
| Glaxosmithkline, LLC. | $284.52 | 2022-2024 | Blenrep |
| Genmab U.S., INC. | $236.66 | 2023-2024 | Epkinly |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $169.73 | 2021-2023 | Rylaze |
| Alexion Pharmaceuticals, INC. | $154.52 | 2022-2023 | Ultomiris |
| Morphosys, US INC. | $137.76 | 2023 | Monjuvi |
| Acrotech Biopharma INC. | $114.54 | 2021 | |
| Janssen Biotech, INC. | $108.37 | 2020-2022 | |
| Siemens Medical Solutions USA, INC. | $91.80 | 2023 | Versant Kpcr Molecular System Sp |
| Celgene Corporation | $71.43 | 2021 | |
| Karyopharm Therapeutics INC. | $32.35 | 2021 | |
| 180 Medical, INC. | $30.63 | 2025 | Gentlecath |
| Bayer Healthcare Pharmaceuticals INC. | $28.82 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $27.09 | 2023 | Valchlor |
| Takeda Pharmaceuticals U.S.A., INC. | $24.56 | 2023 | Iclusig |
| Lilly USA, LLC | $15.52 | 2025 | Jaypirca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Rosen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.